ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1248

Accelerated Aging Influences Cardiovascular Disease Risk in Rheumatoid Arthritis

Cynthia S. Crowson1, Terry M. Therneau1, John M. Davis III2, Veronique L. Roger3, Eric L. Matteson2 and Sherine E. Gabriel4, 1Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 2Rheumatology, Mayo Clinic, Rochester, MN, 3Health Sciences Research and Cardiology, Mayo Clinic, Rochester, MN, 4Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects II: Clinical Features & Comorbidity/Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: People with rheumatoid arthritis (RA) suffer an excess burden of cardiovascular disease (CVD), yet standard risk assessments designed for the general population do not accurately predict their CVD risk. The purpose of this study was to identify traditional CVD risk factors that have a significantly different impact on CVD development in the presence of RA. Recognition of potentially distinctive contributions of CVD risk factors in RA could inform the development of improved CVD risk assessment tools for patient management.

Methods: A population-based inception cohort of RA subjects aged ≥30 years who fulfilled 1987 ACR criteria for RA between 1-1-1988 and 1-1-2008 was assembled and followed until death, migration, or 12-31-2008. Medical records were reviewed to ascertain the presence of CVD risk factors (age, blood pressure, lipids, smoking, and diabetes mellitus) at RA incidence and to ascertain the development of CVD (myocardial infarction, CVD death, angina, heart failure, stroke and intermittent claudication) during follow-up. The 10-year Framingham risk score (FRS) for CVD was calculated. Cox models were used to examine the effects of CVD risk factors included in the FRS in patients with RA, and whether RA disease characteristics (e.g., rheumatoid factor [RF] positivity, acute phase reactants, extra-articular manifestations) modify the effects of CVD risk factors. Models were adjusted for the FRS and stratified by sex.

Results: The study included 525 patients with RA without prior CVD (mean age: 55 years, 71% women; 68% RF positive). The patients were followed for a mean of 8.4 years, during which 84 developed CVD (47 women, 37 men). The FRS predicted only 45.7 events (23.3 women, 22.4 men). Essentially all of the excess events (37.2 of 38.3) were among the RF-positive patients. Analysis of CVD risk factors revealed a greater effect of age on the risk of developing CVD among RF-positive but not RF-negative patients.  As estimated by the FRS, the effect of age on CVD risk in the RF-positive group was nearly double its effect in the general population (p<0.001). The impact of this additional aging effect was negligible for patients younger than 50 years, when CVD risk in the general population is generally low. However, the impact was observed to increase exponentially as CVD risk rose with age. For example, patients over 65 years with RF-positive RA had similar CVD risk as persons in the general population aged >90 years. The unique influence of age in RF-positive RA was not explained by other CVD risk factors or RA disease characteristics. Acute phase reactants and severe extra-articular manifestations also appear to influence CVD risk in RF positive RA after accounting for this additional age effect.

Conclusion: The results revealed an exponentially increasing effect of age on CVD risk in patients who have seropositive RA, supporting prior reports of accelerated aging in this disease. In contrast, the impact of age on CVD risk among RF-negative patients was similar to the general population.  These findings suggest that the advent of CVD risk scores that better account for accelerated aging and other factors in RF-positive patients could improve CVD risk assessment for persons with RA.


Disclosure:

C. S. Crowson, Pfizer Inc, 2; T. M. Therneau,

Pfizer Inc,

2;

J. M. Davis III,
None;

V. L. Roger,
None;

E. L. Matteson,

Pfizer Inc,

2;

S. E. Gabriel,

Pfizer Inc,

2,

Roche Pharmaceuticals,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/accelerated-aging-influences-cardiovascular-disease-risk-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology